Literature DB >> 30219847

Nuclear localization and phosphorylation modulate pathological effects of alpha-synuclein.

Raquel Pinho1,2, Isabel Paiva1, Kristina Gotovac Jercic3, Luis Fonseca-Ornelas4, Ellen Gerhardt1, Christiane Fahlbusch1, Paula Garcia-Esparcia5, Cemil Kerimoglu6, Maria A S Pavlou1, Anna Villar-Piqué1, Éva Szego1, Tomás Lopes da Fonseca1, Francesca Odoardi7, Szabolcs Soeroes8,9, Ana Cristina Rego10, Wolfgang Fischle8,11, Jens C Schwamborn12, Thomas Meyer13, Sebastian Kügler14, Isidre Ferrer5, Johannes Attems15, André Fischer6,16, Stefan Becker4, Markus Zweckstetter4,14,17, Fran Borovecki3,18, Tiago F Outeiro1,15,19,20.   

Abstract

Alpha-synuclein (aSyn) is a central player in Parkinson's disease (PD) but the precise molecular mechanisms underlying its pathogenicity remain unclear. It has recently been suggested that nuclear aSyn may modulate gene expression, possibly via interactions with DNA. However, the biological behavior of aSyn in the nucleus and the factors affecting its transcriptional role are not known. Here, we investigated the mechanisms underlying aSyn-mediated transcription deregulation by assessing its effects in the nucleus and the impact of phosphorylation in these dynamics. We found that aSyn induced severe transcriptional deregulation, including the downregulation of important cell cycle-related genes. Importantly, transcriptional deregulation was concomitant with reduced binding of aSyn to DNA. By forcing the nuclear presence of aSyn in the nucleus (aSyn-NLS), we found the accumulation of high molecular weight aSyn species altered gene expression and reduced toxicity when compared with the wild-type or exclusively cytosolic protein. Interestingly, nuclear localization of aSyn, and the effect on gene expression and cytotoxicity, was also modulated by phosphorylation on serine 129. Thus, we hypothesize that the role of aSyn on gene expression and, ultimately, toxicity, may be modulated by the phosphorylation status and nuclear presence of different aSyn species. Our findings shed new light onto the subcellular dynamics of aSyn and unveil an intricate interplay between subcellular location, phosphorylation and toxicity, opening novel avenues for the design of future strategies for therapeutic intervention in PD and other synucleinopathies.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30219847     DOI: 10.1093/hmg/ddy326

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  47 in total

1.  Glial α-synuclein promotes neurodegeneration characterized by a distinct transcriptional program in vivo.

Authors:  Abby L Olsen; Mel B Feany
Journal:  Glia       Date:  2019-07-03       Impact factor: 7.452

Review 2.  Dynamic behaviors of α-synuclein and tau in the cellular context: New mechanistic insights and therapeutic opportunities in neurodegeneration.

Authors:  Fred Yeboah; Tae-Eun Kim; Anke Bill; Ulf Dettmer
Journal:  Neurobiol Dis       Date:  2019-07-24       Impact factor: 5.996

Review 3.  Genetics of synucleins in neurodegenerative diseases.

Authors:  José Brás; Elizabeth Gibbons; Rita Guerreiro
Journal:  Acta Neuropathol       Date:  2020-08-01       Impact factor: 17.088

Review 4.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

Review 5.  α-Synuclein in Parkinson's disease: causal or bystander?

Authors:  Peter Riederer; Daniela Berg; Nicolas Casadei; Fubo Cheng; Joseph Classen; Christian Dresel; Wolfgang Jost; Rejko Krüger; Thomas Müller; Heinz Reichmann; Olaf Rieß; Alexander Storch; Sabrina Strobel; Thilo van Eimeren; Hans-Ullrich Völker; Jürgen Winkler; Konstanze F Winklhofer; Ullrich Wüllner; Friederike Zunke; Camelia-Maria Monoranu
Journal:  J Neural Transm (Vienna)       Date:  2019-06-25       Impact factor: 3.575

6.  The mechanistic role of alpha-synuclein in the nucleus: impaired nuclear function caused by familial Parkinson's disease SNCA mutations.

Authors:  Vivian Chen; Malik Moncalvo; Dominic Tringali; Lidia Tagliafierro; Ahila Shriskanda; Ekaterina Ilich; Wendy Dong; Boris Kantor; Ornit Chiba-Falek
Journal:  Hum Mol Genet       Date:  2020-11-04       Impact factor: 6.150

Review 7.  A multi-faceted genotoxic network of alpha-synuclein in the nucleus and mitochondria of dopaminergic neurons in Parkinson's disease: Emerging concepts and challenges.

Authors:  Velmarini Vasquez; Joy Mitra; Haibo Wang; Pavana M Hegde; K S Rao; Muralidhar L Hegde
Journal:  Prog Neurobiol       Date:  2019-12-18       Impact factor: 11.685

8.  Physiological and pathological roles of LRRK2 in the nuclear envelope integrity.

Authors:  Vered Shani; Hazem Safory; Raymonde Szargel; Ninghan Wang; Tsipora Cohen; Fatimah Abd Elghani; Haya Hamza; Mor Savyon; Inna Radzishevsky; Lihi Shaulov; Ruth Rott; Kah-Leong Lim; Christopher A Ross; Rina Bandopadhyay; Hui Zhang; Simone Engelender
Journal:  Hum Mol Genet       Date:  2019-12-01       Impact factor: 6.150

9.  Molecular insights into α-synuclein interaction with individual human core histones, linker histone, and dsDNA.

Authors:  Sneha Jos; Hemanga Gogoi; Thazhe Kootteri Prasad; Manjunath A Hurakadli; Neelagandan Kamariah; Balasundaram Padmanabhan; Sivaraman Padavattan
Journal:  Protein Sci       Date:  2021-08-19       Impact factor: 6.993

Review 10.  Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease.

Authors:  Luis M A Oliveira; Thomas Gasser; Robert Edwards; Markus Zweckstetter; Ronald Melki; Leonidas Stefanis; Hilal A Lashuel; David Sulzer; Kostas Vekrellis; Glenda M Halliday; Julianna J Tomlinson; Michael Schlossmacher; Poul Henning Jensen; Julia Schulze-Hentrich; Olaf Riess; Warren D Hirst; Omar El-Agnaf; Brit Mollenhauer; Peter Lansbury; Tiago F Outeiro
Journal:  NPJ Parkinsons Dis       Date:  2021-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.